Shantou Central Hospital

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer4 trials
• Chronic kidney disease2 trials
• Atrial fibrillation1 trial
• Coronary artery disease1 trial
• Fabry disease1 trial
• IgA nephropathy1 trial
• Osteoarthritis1 trial
• Stroke1 trial

Phase

• Phase 37 trials
• Phase 41 trial

Status

• Active, not recruiting5 trials
• Recruiting3 trials
• Not yet recruiting2 trials
• Completed1 trial
• Enrolling by invitation1 trial

Lead sponsor

• Boehringer Ingelheim1 trial
• Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.1 trial
• GeneQuantum Healthcare (Suzhou) Co., Ltd.1 trial
• Guangdong Hongzhi Health Technology1 trial
• Guangdong Provincial People's Hospital1 trial
• and 7 more

Running trials

• Recruiting

  A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease

  NCT07187440· Takeda· Source

  Contact: Ying Wang (principal investigator)

• Recruiting

  A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

  NCT07003074· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

  Contact: Zhiyong Wu, Doctor

• Recruiting

  A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

  NCT07673029· Phase 3· GeneQuantum Healthcare (Suzhou) Co., Ltd.· Source

  Contact: Zhiyong Wu

• Enrolling by invitation

  Catheter Ablation for Functional Mitral Regurgitation in Persistent Atrial Fibrillation: Development and Validation of a Predictive Model-A Multicenter Prospective Cohort Study

  NCT07096219· Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University· Source

• Active, not recruiting

  EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

  NCT06531824· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  Methylprednisolone Adjunctive to Endovascular Thrombectomy for Stroke

  NCT06360458· Phase 3· Wan-Jin Chen· Source

• Active, not recruiting

  A Study of Telitacicept for IgA Nephropathy (TELIGAN)

  NCT05799287· Phase 3· RemeGen Co., Ltd.· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of HLX11 vs. EU-Perjeta® in the Neoadjuvant Therapy of HER2-Positive and HR-Negative Early-stage or Locally Advanced Breast Cancer

  NCT05346224· Phase 3· Shanghai Henlius Biotech· Source

• Not yet recruiting

  Optimized Antiplatelet Therapy in Patients With CHD After Implantation of NeoVas™ BRS System

  NCT04995159· Lepu Medical Technology (Beijing) Co., Ltd.· Source

  Contact: Zhixiong Cai

• Active, not recruiting

  ASPIrin in Reducing Events in Dialysis ( ASPIRED )

  NCT04381143· Phase 4· Guangdong Provincial People's Hospital· Source

• Recruiting

  Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer

  NCT04263298· Phase 3· Herui Yao· Source

  Contact: Zhiyong Wu, MD

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Metastatic breast cancer3 recruiting
• Atrial fibrillation1 recruiting
• Coronary artery disease1 recruiting
• Fabry disease1 recruiting

Closed trials

• Completed

  Study on the Use of a Concentrated Growth Factor Preparation Kit for the Treatment of Knee Osteoarthritis

  NCT06869200· Guangdong Hongzhi Health Technology· Source